Deerland Probiotics & Enzymes has announced the publication of a clinical study examining the immune support effects of Bacillus subtilis DE111.
The study, “Examining the Gastrointestinal and Immunomodulatory Effects of the Novel Probiotic Bacillus subtilis DE111,” published in the International Journal of Molecular Sciences, was an IRB-approved, randomised, double-blind, placebo-controlled study involving 44 healthy adults (aged 20 to 62). Participants consumed either <B. subtilis DE111 (1 billion CFU) or placebo daily for four weeks. The researchers examined peripheral blood mononuclear cells (PBMCs) at basal levels pre- and post-study, as well as in response to stimulation with bacterial lipopolysaccharide (LPS), which encourages neutrophils, macrophages and other innate immune cells to release pro-inflammatory cytokines. The results of the study reportedly indicated DE111 can support a healthy immune system and a robust immune response.
After four weeks of supplementing with DE111, the authors found, participants displayed immunomodulatory and anti-inflammatory effects on several T cell subsets. “This is supported by the observed reduction in immune cell populations within the basal state,” they said. “The downregulation of these cell types in circulation may implicate an overall anti-inflammatory state demonstrated by the decrease in peripheral surveillance and effector cell types.”
Another proposed mechanism suggests DE111 ingestion improved the gut barrier function resulting in less circulating LPS, thereby reducing inflammation levels. In addition, the authors found those in the DE111 group exhibited an increase in anti-inflammatory immune cell populations in response to ex vivo LPS stimulation of PBMCs, which is indicative of a more robust response to prime the immune system. In summary, they said, this study shows supplementing with B. subtilis DE111 “modulates the host immune system through anti-inflammatory and suppressive action on both innate and adaptive cell types.”
“This newly published study substantiates the efficacy of B. subtilis DE111 for use in products that address the most common concerns of the day– a strong immune system with a quick response to foreign invaders,” said Dr John Deaton, VP of Science and Technology at Deerland Probiotics & Enzymes. “The latest publication adds to an impressive list of clinical studies showing DE111’s impact on digestive, children’s and cardio health and sports performance/recovery.”
